Compare TYRA & ATEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TYRA | ATEN |
|---|---|---|
| Founded | 2018 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.9B |
| IPO Year | 2021 | 2014 |
| Metric | TYRA | ATEN |
|---|---|---|
| Price | $33.74 | $28.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 6 |
| Target Price | ★ $47.50 | $26.33 |
| AVG Volume (30 Days) | 749.1K | ★ 858.9K |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 0.90% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.17 |
| Revenue | N/A | ★ $235,429,000.00 |
| Revenue This Year | N/A | $13.02 |
| Revenue Next Year | N/A | $10.82 |
| P/E Ratio | ★ N/A | $166.12 |
| Revenue Growth | N/A | ★ 2.36 |
| 52 Week Low | $8.75 | $16.52 |
| 52 Week High | $40.65 | $28.66 |
| Indicator | TYRA | ATEN |
|---|---|---|
| Relative Strength Index (RSI) | 43.61 | 66.31 |
| Support Level | $33.29 | $17.08 |
| Resistance Level | $33.99 | N/A |
| Average True Range (ATR) | 1.98 | 0.92 |
| MACD | -0.02 | -0.06 |
| Stochastic Oscillator | 30.44 | 77.81 |
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
A10 Networks Inc is a provider of secure application and network infrastructure solutions for enterprises and service providers across on-premises, hybrid cloud, and distributed environments. The company's offerings include application delivery and traffic management, distributed denial-of-service (DDoS) protection, application and API security, and centralized management. It serves customers across multiple industries, including telecommunications, technology, financial services, public sector, industrial, retail, gaming, and education. The majority of the company's revenue is derived from the sale of secure networking and cybersecurity solutions and related maintenance and support services.